Jing Ai

发表

Enhancing the cellular anti-proliferation activity of pyridazinones as c-met inhibitors using docking analysis.

Youhong Hu, M. Geng, Dong Lu, 2015, European journal of medicinal chemistry.

Sulfated polymannuroguluronate, a novel anti‐acquired immune deficiency syndrome drug candidate, blocks neuroinflammatory signalling by targeting the transactivator of transcription (Tat) protein

M. Geng, W. Xia, Limei Wang, 2006, Journal of neurochemistry.

Design, Synthesis, and Pharmacological Evaluation of Novel Multisubstituted Pyridin-3-amine Derivatives as Multitargeted Protein Kinase Inhibitors for the Treatment of Non-Small Cell Lung Cancer.

Hong Liu, M. Zheng, M. Geng, 2017, Journal of medicinal chemistry.

Design, synthesis and biological evaluation of a series of novel 2-benzamide-4-(6-oxy-N-methyl-1-naphthamide)-pyridine derivatives as potent fibroblast growth factor receptor (FGFR) inhibitors.

M. Geng, Ruimin Huang, L. Xing, 2018, European journal of medicinal chemistry.

Investigation on the 1,6-naphthyridine motif: discovery and SAR study of 1H-imidazo[4,5-h][1,6]naphthyridin-2(3H)-one-based c-Met kinase inhibitors.

M. Geng, Jian-Ping Lin, Yong Wang, 2013, Organic & biomolecular chemistry.

Design and synthesis of novel benzo[d]oxazol-2(3H)-one derivatives bearing 7-substituted-4-enthoxyquinoline moieties as c-Met kinase inhibitors.

Youhong Hu, M. Geng, Dong Lu, 2016, European journal of medicinal chemistry.

Discovery of novel type II c-Met inhibitors based on BMS-777607.

Wei Zhang, M. Geng, Yingxia Li, 2014, European journal of medicinal chemistry.

The Novel RET Inhibitor SYHA1815 Inhibits RET-Driven Cancers and Overcomes Gatekeeper Mutations by Inducing G1 Cell-Cycle Arrest through c-Myc Downregulation

Yi Chen, Youhong Hu, Yan-fen Fang, 2021, Molecular Cancer Therapeutics.

Discovery of 4-chloro-3-(5-(pyridin-3-yl)-1,2,4-oxadiazole-3-yl)benzamides as novel RET kinase inhibitors.

Youhong Hu, M. Geng, R. Sheng, 2016, Bioorganic & medicinal chemistry letters.

Sulfated polymannuroguluronate inhibits Tat-induced SLK cell adhesion via a novel binding site, a KKR spatial triad

M. Geng, Yan-lin Wu, B. Xiong, 2011, Acta Pharmacologica Sinica.

Optimization of 1H-indazol-3-amine derivatives as potent fibroblast growth factor receptor inhibitors.

Yingxia Li, Dingding Gao, Jing Ai, 2017, Bioorganic & medicinal chemistry letters.

Preclinical evaluation of 3D185, a novel potent inhibitor of FGFR1/2/3 and CSF-1R, in FGFR-dependent and macrophage-dominant cancer models

Yi Chen, Jian Ding, M. Geng, 2019, Journal of Experimental & Clinical Cancer Research.

The role of histone deacetylase 7 (HDAC7) in cancer cell proliferation: regulation on c-Myc

Qin Chen, Jian Ding, Lin-jiang Tong, 2011, Journal of Molecular Medicine.

Discovering potent inhibitors against c-Met kinase: molecular design, organic synthesis and bioassay.

Kaixian Chen, Hualiang Jiang, Hong Liu, 2012, Organic & biomolecular chemistry.

Discovery of 10H-Benzo[b]pyrido[2,3-e][1,4]oxazine AXL Inhibitors via Structure-Based Drug Design Targeting c-Met Kinase.

Qiu-feng Liu, H. Su, Yin-chun Ji, 2022, Journal of medicinal chemistry.

Novel carbon-bridged citrinin dimers from a volcano ash-derived fungus Penicillium citrinum and their cytotoxic and cell cycle arrest activities

T. Zhu, L. Du, Dehai Li, 2010 .

18F-FDG PET as an imaging biomarker for the response to FGFR-targeted therapy of cancer cells via FGFR-initiated mTOR/HK2 axis

Hu Zhou, Ruimin Huang, Yuchen Jiang, 2022, Theranostics.

Synthesis and c-Met kinase inhibition of 3,5-disubstituted and 3,5,7-trisubstituted quinolines: identification of 3-(4-acetylpiperazin-1-yl)-5-(3-nitrobenzylamino)-7- (trifluoromethyl)quinoline as a novel anticancer agent.

Yi Chen, M. Geng, Gang Liu, 2011, Journal of medicinal chemistry.

Discovery of novel 2-aminopyridine-3-carboxamides as c-Met kinase inhibitors.

Hualiang Jiang, Hong Liu, Zhongjie Liang, 2012, Bioorganic & medicinal chemistry.

Expeditious one-pot synthesis of C3-piperazinyl-substituted quinolines: key precursors to potent c-Met inhibitors.

M. Geng, Gang Liu, Yuanxiang Wang, 2011, Organic & biomolecular chemistry.

The Discovery and Development of a Series of Pyrazolo[3,4-d]pyridazinone Compounds as Novel Covalent Fibroblast Growth Factor Receptor (FGFR) Inhibitors by Rational Drug Design.

Hualiang Jiang, Yechun Xu, Hong Liu, 2019, Journal of medicinal chemistry.

Pyridazinone derivatives displaying highly potent and selective inhibitory activities against c-Met tyrosine kinase.

Youhong Hu, M. Geng, Dong Lu, 2016, European journal of medicinal chemistry.

Discovery of Substituted 1H-Pyrazolo[3,4-b]pyridine Derivatives as Potent and Selective FGFR Kinase Inhibitors.

C. Luo, M. Geng, Bin Zhao, 2016, ACS medicinal chemistry letters.

Multisubstituted quinoxalines and pyrido[2,3-d]pyrimidines: synthesis and SAR study as tyrosine kinase c-Met inhibitors.

Yechun Xu, M. Geng, Qiu-feng Liu, 2012, Bioorganic & medicinal chemistry letters.

Discovery of novel c-Met kinase inhibitors bearing a thieno[2,3-d]pyrimidine or furo[2,3-d]pyrimidine scaffold.

Yi Chen, M. Geng, Yuanxiang Wang, 2011, Bioorganic & medicinal chemistry.

Discovery of 6-(difluoro(6-(4-fluorophenyl)-[1,2,4]triazolo[4,3-b][1,2,4]triazin-3-yl)methyl)quinoline as a highly potent and selective c-Met inhibitor.

Yechun Xu, M. Geng, Qiu-feng Liu, 2016, European journal of medicinal chemistry.

Synthesis and structure-activity relationship study of pyrazolo[3,4-d]pyrimidines as tyrosine kinase RET inhibitors.

M. Geng, Hongchun Liu, Yin-chun Ji, 2017, Bioorganic & medicinal chemistry letters.

Synthesis and biological evaluation of 2-amino-5-aryl-3-benzylthiopyridine scaffold based potent c-Met inhibitors.

Cheng Luo, Ying Wang, Zhongjie Liang, 2013, Bioorganic & medicinal chemistry.

Design and optimization of a series of 1-sulfonylpyrazolo[4,3-b]pyridines as selective c-Met inhibitors.

Jian Ding, M. Geng, B. Xiong, 2015, Journal of medicinal chemistry.

Design and synthesis of 3,3'-biscoumarin-based c-Met inhibitors.

F. Nan, M. Geng, Lin-qian Yu, 2014, Organic & biomolecular chemistry.

Prenylated indole diketopiperazines from the marine-derived fungus Aspergillus versicolor.

M. Geng, T. Zhu, Dehai Li, 2014, The Journal of organic chemistry.

Discovery of 2,4-diarylaminopyrimidines bearing a resorcinol motif as novel ALK inhibitors to overcome the G1202R resistant mutation.

M. Geng, Yin-chun Ji, Zilan Song, 2018, European journal of medicinal chemistry.

Discovery of 3-(5'-Substituted)-Benzimidazole-5-(1-(3,5-dichloropyridin-4-yl)ethoxy)-1H-indazoles as Potent Fibroblast Growth Factor Receptor Inhibitors: Design, Synthesis, and Biological Evaluation.

C. Luo, M. Geng, Fanwang Meng, 2016, Journal of medicinal chemistry.

A divergent approach to benzylisoquinoline-type and oxoaporphine alkaloids via regioselective direct ring metalation of alkoxy isoquinolines

Wei Zhang, S. Ley, M. Geng, 2015 .

Novel 2,4-Diarylaminopyrimidine Analogues (DAAPalogues) Showing Potent c-Met/ALK Multikinase Inhibitory Activities.

Yi Chen, M. Geng, Yin-chun Ji, 2014, ACS medicinal chemistry letters.

Aspergiolides C and D: spirocyclic aromatic polyketides with potent protein kinase c-Met inhibitory effects.

G. Bringmann, M. Geng, Ying Wang, 2011, Chemistry.

Potent HGF/c-Met axis inhibitors from Eucalyptus globulus: the coupling of phloroglucinol and sesquiterpenoid is essential for the activity.

Jian Ding, M. Geng, J. Yue, 2012, Journal of medicinal chemistry.

Trigochinins A-C: three new daphnane-type diterpenes from Trigonostemon chinensis.

M. Geng, J. Yue, Hua-dong Chen, 2010, Organic letters.

Trigochilides A and B, two highly modified daphnane-type diterpenoids from Trigonostemon chinensis.

M. Geng, J. Yue, Hua-dong Chen, 2009, Organic letters.

Trigochilides A and B, two highly modified daphnane-type diterpenoids from Trigonostemon chinensis.

M. Geng, J. Yue, Hua-dong Chen, 2009, Organic letters.

Anti-inflammatory Eudesmane Sesquiterpenoids from Artemisia hedinii.

Sheng Yao, C. Ke, Chunping Tang, 2021, Journal of natural products.

Polymeric immunoglobulin receptor promotes tumor growth in hepatocellular carcinoma

Min Huang, Yi Chen, Jian Ding, 2017, Hepatology.

Prenylated indole diketopiperazines from the marine-derived fungus Aspergillus versicolor.

M. Geng, T. Zhu, Dehai Li, 2014, The Journal of organic chemistry.

Anthraquinone Derivatives as Potent Inhibitors of c-Met Kinase and the Extracellular Signaling Pathway.

Hualiang Jiang, Hong Liu, M. Zheng, 2013, ACS medicinal chemistry letters.

Preclinical evaluation of 3D185, a novel potent inhibitor of FGFR1/2/3 and CSF-1R, in FGFR-dependent and macrophage-dominant cancer models

Yi Chen, Jian Ding, M. Geng, 2019, Journal of experimental & clinical cancer research : CR.

The Secretome Engages STAT3 to Favor a Cytokine-rich Microenvironment in Mediating Acquired Resistance to FGFR Inhibitors

Yi Chen, Jian Ding, M. Geng, 2018, Molecular Cancer Therapeutics.

c-Myc Alteration Determines the Therapeutic Response to FGFR Inhibitors

Min Huang, Yi Chen, Jian Ding, 2016, Clinical Cancer Research.

Development of Heat Shock Protein (Hsp90) Inhibitors To Combat Resistance to Tyrosine Kinase Inhibitors through Hsp90-Kinase Interactions.

Jian Ding, M. Geng, Hongchun Liu, 2016, Journal of medicinal chemistry.

Discovery of a new series of imidazo[1,2-a]pyridine compounds as selective c-Met inhibitors

Dong-mei Zhao, M. Geng, B. Xiong, 2016, Acta Pharmacologica Sinica.

Discovery of novel 2,4-diarylaminopyrimidine analogues (DAAPalogues) showing potent inhibitory activities against both wild-type and mutant ALK kinases.

Jian Ding, M. Geng, Zilan Song, 2015, Journal of medicinal chemistry.

SOMCL-863, a novel, selective and orally bioavailable small-molecule c-Met inhibitor, exhibits antitumor activity both in vitro and in vivo.

Min Huang, Jian Ding, M. Geng, 2014, Cancer letters.

DW14383 is an irreversible pan-FGFR inhibitor that suppresses FGFR-dependent tumor growth in vitro and in vivo

Jian Ding, Yin-chun Ji, W. Duan, 2020, Acta Pharmacologica Sinica.

Identification of metabolic vulnerabilities of receptor tyrosine kinases-driven cancer

Min Huang, Jian Ding, Hanlin Zeng, 2019, Nature Communications.

SOMG-833, a Novel Selective c-MET Inhibitor, Blocks c-MET–Dependent Neoplastic Effects and Exerts Antitumor Activity

Min Huang, Yi Chen, Jian Ding, 2014, The Journal of Pharmacology and Experimental Therapeutics.

Discovery and SAR study of c-Met kinase inhibitors bearing an 3-amino-benzo[d]isoxazole or 3-aminoindazole scaffold.

M. Geng, Yin-chun Ji, Qizheng Yao, 2015, Bioorganic & medicinal chemistry.

Discovery of a series of dimethoxybenzene FGFR inhibitors with 5H-pyrrolo[2,3-b]pyrazine scaffold: structure–activity relationship, crystal structural characterization and in vivo study

M. Geng, B. Xiong, Jing-kang Shen, 2018, Acta pharmaceutica Sinica. B.

An orally available tyrosine kinase ALK and RET dual inhibitor bearing the tetracyclic benzo[b]carbazolone core.

M. Geng, Yin-chun Ji, L. Xing, 2016, European journal of medicinal chemistry.

Novel tetracyclic benzo[b]carbazolones as highly potent and orally bioavailable ALK inhibitors: design, synthesis, and structure-activity relationship study.

Jian Ding, M. Geng, L. Xing, 2015, European journal of medicinal chemistry.

Design, synthesis and pharmacological evaluation of 2-(thiazol-2-amino)-4-arylaminopyrimidines as potent anaplastic lymphoma kinase (ALK) inhibitors.

Jian Ding, M. Geng, Yin-chun Ji, 2014, European journal of medicinal chemistry.

Structural Optimization of Fibroblast Growth Factor Receptor Inhibitors for Treating Solid Tumors.

Xutong Li, M. Geng, Hong Liu, 2023, Journal of medicinal chemistry.

Design, synthesis and biological evaluation of pyrazolo[3,4-d]pyridazinone derivatives as covalent FGFR inhibitors

Hualiang Jiang, Hong Liu, M. Zheng, 2020, Acta pharmaceutica Sinica. B.

Discovery of Anilinopyrimidines as Dual Inhibitors of c-Met and VEGFR-2: Synthesis, SAR, and Cellular Activity.

Yechun Xu, M. Geng, Qiu-feng Liu, 2014, ACS medicinal chemistry letters.

Discovery of novel Ponatinib analogues for reducing KDR activity as potent FGFRs inhibitors.

Youhong Hu, M. Geng, Dong Lu, 2017, European journal of medicinal chemistry.

Discovery of a potent tyrosine kinase AXL inhibitor bearing the 3-((2,3,4,5-tetrahydro-1H-benzo[d]azepin-7-yl)amino)pyrazine core.

Yin-chun Ji, L. Xing, Zilan Song, 2019, Bioorganic & medicinal chemistry letters.

The Marine-Derived Oligosaccharide Sulfate MS80, a Novel Transforming Growth Factor β1 Inhibitor, Reverses Epithelial Mesenchymal Transition Induced by Transforming Growth Factor-β1 and Suppresses Tumor Metastasis

Bi Chen, Jing Ai, Wenjie You, 2016, The Journal of Pharmacology and Experimental Therapeutics.

SOMCL-085, a novel multi-targeted FGFR inhibitor, displays potent anticancer activity in FGFR-addicted human cancer models

Wei-ren Liu, Yinghong Shi, Zhen-Bin Ding, 2017, Acta Pharmacologica Sinica.

The Role of Polymeric Immunoglobulin Receptor in Inflammation-Induced Tumor Metastasis of Human Hepatocellular Carcinoma

Min Huang, Yi Chen, H. Xu, 2011, Journal of the National Cancer Institute.

Discovery of pyrrolo[2,3-d]pyrimidine derivatives as potent Axl inhibitors: Design, synthesis and biological evaluation.

M. Geng, Yin-chun Ji, W. Duan, 2021, European journal of medicinal chemistry.

Design, Synthesis, and Pharmacological Evaluation of Biaryl-Containing PD-1/PD-L1 Interaction Inhibitors Bearing a Unique Difluoromethyleneoxy Linkage.

M. Geng, L. Xing, Bo Liu, 2021, Journal of medicinal chemistry.

Novel 5-(benzyloxy)pyridin-2(1H)-one derivatives as potent c-Met inhibitors.

Weiliang Zhu, Hualiang Jiang, Hong Liu, 2013, Bioorganic & medicinal chemistry letters.

Metabolism-based structure optimization: Discovery of a potent and orally available tyrosine kinase ALK inhibitor bearing the tetracyclic benzo[b]carbazolone core.

M. Geng, Yin-chun Ji, L. Xing, 2016, Bioorganic & medicinal chemistry letters.

Design, synthesis and biological evaluation of pyrazolylaminoquinazoline derivatives as highly potent pan-fibroblast growth factor receptor inhibitors.

Jingwei Shao, M. Geng, Chen Wang, 2016, Bioorganic & medicinal chemistry letters.

Evaluation of in vitro and in vivo activity of a multityrosine kinase inhibitor, AL3810, against human thyroid cancer

Yi Chen, Jian Ding, M. Geng, 2017, Acta Pharmacologica Sinica.

Simm530, a novel and highly selective c-Met inhibitor, blocks c-Met-stimulated signaling and neoplastic activities

Jian Ding, M. Geng, Wei-ren Liu, 2016, Oncotarget.

Laeviganoids A-T, ent-Clerodane-Type Diterpenoids from Croton laevigatus.

J. Yue, Qun-fang Liu, Bin-Shan Zhou, 2023, Journal of natural products.

Identification of metabolic vulnerabilities of receptor tyrosine kinases-driven cancer

Min Huang, Jian Ding, Hanlin Zeng, 2019, Nature Communications.

O‐Linked Triazolotriazines: Potent and Selective c‐Met Inhibitors

Zhongjie Liang, C. Luo, M. Geng, 2012, ChemMedChem.

Discovery of 3H‐Imidazo[4,5‐b]pyridines as Potent c‐Met Kinase Inhibitors: Design, Synthesis, and Biological Evaluation

Yi Chen, M. Geng, B. Xiong, 2012, ChemMedChem.

SYK-mediated epithelial cell state is associated with response to c-Met inhibitors in c-Met-overexpressing lung cancer

M. Geng, Xuchao Zhang, Zuoquan Xie, 2023, Signal transduction and targeted therapy.

Preclinical Evaluation of SCC244 (Glumetinib), a Novel, Potent, and Highly Selective Inhibitor of c-Met in MET-dependent Cancer Models

Yi Chen, Jian Ding, M. Geng, 2017, Molecular Cancer Therapeutics.

Evaluation of Deuterium-Labeled JNJ38877605: Pharmacokinetic, Metabolic, and in Vivo Antitumor Profiles.

W. Duan, Jing Ai, Xia Peng, 2018, Chemical research in toxicology.

Further SAR studies on 3,5-diamino-7-trifluoromethylquinolines as highly potent tyrosine kinase c-Met inhibitors: efforts to correct hERG inhibition

Yi Chen, M. Geng, Zhaobing Gao, 2012 .

Discovery and optimization of a series of 3-substituted indazole derivatives as multi-target kinase inhibitors for the treatment of lung squamous cell carcinoma.

M. Geng, B. Xiong, Yuchen Jiang, 2019, European journal of medicinal chemistry.

Yhhu3813 is a novel selective inhibitor of c-Met Kinase that inhibits c-Met-dependent neoplastic phenotypes of human cancer cells

Min Huang, Yi Chen, Jian Ding, 2013, Acta Pharmacologica Sinica.

A Triad of Lys12, Lys41, Arg78 Spatial Domain, a Novel Identified Heparin Binding Site on Tat Protein, Facilitates Tat-Driven Cell Adhesion

Hualiang Jiang, M. Zheng, M. Geng, 2008, PloS one.

α2,6-hyposialylation of c-Met abolishes cell motility of ST6Gal-I-knockdown HCT116 cells

Jian Ding, M. Geng, J. Qian, 2009, Acta Pharmacologica Sinica.

SAF-189s, a potent new-generation ROS1 inhibitor, is active against crizotinib-resistant ROS1 mutant-driven tumors

Jian Ding, Yan-fen Fang, M. Geng, 2020, Acta pharmacologica Sinica.

SAF-189s, a potent new-generation ROS1 inhibitor, is active against crizotinib-resistant ROS1 mutant-driven tumors

Jian Ding, Yan-fen Fang, M. Geng, 2020, Acta Pharmacologica Sinica.

Structure-Based Discovery of a Series of 5H-Pyrrolo[2,3-b]pyrazine FGFR Kinase Inhibitors

Yechun Xu, Jian Ding, Qiu-feng Liu, 2018, Molecules.

Discovery and Biological Evaluation of a Series of Pyrrolo[2,3-b]pyrazines as Novel FGFR Inhibitors

Tongchao Liu, B. Xiong, Hongchun Liu, 2017, Molecules.

Cyanobacterial peptides as a prototype for the design of cathepsin D inhibitors

Wei Zhang, Keting Bao, Shuai Tang, 2017, Journal of peptide science : an official publication of the European Peptide Society.

Farnesoid X Receptor Constructs an Immunosuppressive Microenvironment and Sensitizes FXRhighPD-L1low NSCLC to Anti–PD-1 Immunotherapy

Shan Xue, H. Qin, Bi Chen, 2019, Cancer Immunology Research.

Identification and synthesis of N'-(2-oxoindolin-3-ylidene)hydrazide derivatives against c-Met kinase.

Kaixian Chen, Hualiang Jiang, Hong Liu, 2011, Bioorganic & medicinal chemistry letters.

Discovery of Novel c-Met Inhibitors Bearing a 3-Carboxyl Piperidin-2-one Scaffold

Wei Zhang, M. Geng, Yin-chun Ji, 2014, Molecules.

Discovery of Potent Irreversible Pan-Fibroblast Growth Factor Receptor (FGFR) Inhibitors.

M. Geng, W. Duan, Jun Fan, 2018, Journal of medicinal chemistry.

Simm530, a novel and highly selective c-Met inhibitor, blocks c-Met-stimulated signaling and neoplastic activities

Jian Ding, M. Geng, Yin-chun Ji, 2016, Oncotarget.

Discovery of 3-Aminopyrazole Derivatives as New Potent and Orally Bioavailable AXL Inhibitors.

Licheng Zhou, H. Hur, Zhen Wang, 2022, Journal of medicinal chemistry.

Design, Synthesis, and Biological Evaluation of Novel Imidazo[1,2-a]pyridine Derivatives as Potent c-Met Inhibitors.

X. Chen, Hong Liu, M. Geng, 2015, ACS medicinal chemistry letters.

Synthesis of triazolotriazine derivatives as c-Met inhibitors

Jian Ding, Yin-chun Ji, W. Duan, 2020, Molecular Diversity.

Design, Synthesis and Biological Evaluation of 6-(2,6-Dichloro-3,5-dimethoxyphenyl)-4-substituted-1H-indazoles as Potent Fibroblast Growth Factor Receptor Inhibitors

M. Geng, B. Xiong, Dongmei Zhao, 2016, Molecules.

Expeditious one-pot synthesis of C3-piperazinyl-substituted quinolines: key precursors to potent c-Met inhibitors.

M. Geng, Gang Liu, Yuanxiang Wang, 2011, Organic & biomolecular chemistry.

Energetic factors determining the binding of type I inhibitors to c-Met kinase: experimental studies and quantum mechanical calculations

Bing Xiong, Xin Wang, Jing Ai, 2013, Acta Pharmacologica Sinica.

Identification and synthesis of N'-(2-oxoindolin-3-ylidene)hydrazide derivatives against c-Met kinase.

Kaixian Chen, Hualiang Jiang, Hong Liu, 2011, Bioorganic & medicinal chemistry letters.

Design, synthesis and biological evaluation of novel FGFR inhibitors bearing an indazole scaffold.

Wei Zhang, M. Geng, S. Ren, 2015, Organic & biomolecular chemistry.

Structure-based drug discovery of novel fused-pyrazolone carboxamide derivatives as potent and selective AXL inhibitors

Yu Zhou, Chunpu Li, Yin-chun Ji, 2023, Acta pharmaceutica Sinica. B.

Development of Heat Shock Protein (Hsp90) Inhibitors To Combat Resistance to Tyrosine Kinase Inhibitors through Hsp90-Kinase Interactions.

Jian Ding, M. Geng, Hongchun Liu, 2016, Journal of medicinal chemistry.

Discovery of hematopoietic progenitor kinase 1 inhibitors using machine learning-based screening and free energy perturbation.

Jing Ai, Hefeng Zhang, Meiyu Geng, 2024, Journal of biomolecular structure & dynamics.

13,14-seco withaphysalins from Physalis minima and their inhibitory effects on NLRP3 inflammasome activation.

Sheng Yao, Chunping Tang, Yang Ye, 2024, Bioorganic chemistry.